A Phase 1/2a, trial of SRP-5051 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs SRP-5051 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- 14 Nov 2017 New trial record
- 07 Nov 2017 According to a Sarepta Therapeutics media release, the U.S. FDA has cleared its Investigational New Drug IND application.
- 07 Nov 2017 According to a Sarepta Therapeutics media release, results of this trial will be used to initiate another trial (see profile 290320).